Monitor for the filing of the resale registration statement and watch for any insider trading activity or follow-on commentary on clinical development timelines. The influx of cash extends the runway but adds meaningful dilution; assess whether upcoming catalysts justify the expanded share count.
Price Chart
Executive Summary
Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, with proceeds intended for R&D and general corporate purposes. The offering includes significant participation from major healthcare investors and is expected to close March 11, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Relmada raised $160 million in gross proceeds via a PIPE financing.
- The offering includes 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants for 4,210,527 shares at $4.749 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Proceeds will fund working capital, R&D advancement, and general corporate purposes.
- Major institutional investors participated, including RA Capital, OrbiMed, Janus Henderson, and Balyasny.
- A registration rights agreement requires Relmada to file a resale registration statement with the SEC.
- Closing expected on or about March 11, 2026, subject to customary conditions.
Financial Impact
$160 million gross proceeds; significant near-term dilution from 33.7 million new shares (approx 14.3% of current shares outstanding assuming 235M prior float)
Risk Factors
- Significant shareholder dilution from issuance of ~33.7 million new shares and pre-funded warrants.
- Resale registration could increase near-term selling pressure as investors may flip shares.
- No guarantee that R&D spending will lead to clinical success or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251705 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $4.52 $4.12 | ▼ −8.85% | ▼ −8.63% | $3.60 (−20.35%) |
May 13, 2026 20w ago | S-3ASR | $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $3.60 (+51.48%) |
May 12, 2026 20w ago | 8-K | $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $3.60 (−51.94%) |
Apr 17, 2026 23w ago | DEFA14A | $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $3.60 (−51.15%) |
Apr 3, 2026 25w ago | S-3 | $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $3.60 (−47.83%) |
Mar 19, 2026 28w ago | Press Release | $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $3.60 (−40.69%) |
Mar 12, 2026 29w ago | Press Release | $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $3.60 (−41.46%) |
Mar 9, 2026 29w ago | Press Release | $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $3.60 (−49.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access